Physician profile
Ashley Brown
NPI 1760904619
$846.09
in general payments reported to CMS, 2019-2025
11 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $9.85 · 2023: $585 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $408.49 | 2023 | Invega Sustenna, Invega Trinza |
| Dilon Technologies, INC. | $154.04 | 2023 | Hemoblast Bellows |
| Neurocrine Biosciences, INC. | $101.24 | 2025 | |
| Cochlear Americas | $37.23 | 2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha, Osia Osi300 Implant |
| Azurity Pharmaceuticals, INC. | $27.74 | 2025 | Alvesco |
| Biocryst US Sales Co., LLC | $26.34 | 2025 | Orladeyo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.19 | 2025 | Caplyta |
| Ardelyx, INC. | $22.46 | 2023 | Ibsrela |
| Ars Pharmaceuticals Operations, INC. | $19.27 | 2025 | Neffy |
| Kedrion Biopharma, INC. | $16.24 | 2025 | Rhogam Ultra-Filtered Plus, Koate, Gammaked |
| Genentech USA, INC. | $9.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.